In this preprint study of the RECOVERY clinical trial involving 6,425 hospitalized patients with COVID-19, Horby et al. report that patients receiving a 6 mg daily dose of the corticosteroid dexamethasone had a reduced 28-day mortality compared with those receiving standard of care. Importantly, dexamethasone reduced death by one-third in patients receiving invasive mechanical ventilation and by one-fifth in patients requiring oxygen only but showed no benefit in patients who did not require respiratory support. Overall, the results of this study suggest that dexamethasone, an inexpensive and widely available anti-inflammatory drug, is a valuable treatment for severe cases of COVID-19.
References
Original article
Horby, P. et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. Preprint at medRxiv https://doi.org/10.1101/2020.06.22.20137273 (2020)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Moon, C. Dexamethasone to the rescue. Nat Rev Immunol 20, 463 (2020). https://doi.org/10.1038/s41577-020-0394-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-020-0394-2